Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mabwell Biotechnology
Finance Watch: Aileron, Talaris, Frequency And The Search For Strategic Alternatives
Public Company Edition: Aileron, Talaris and Frequency said they will reduce expenses and seek options for maximizing shareholder returns under tough stock market conditions. However, CureVac and Supernus are among firms recently able to access new cash – $250m and $150m, respectively.
Deal Watch: Sol-Gel To Tackle Gorlin Syndrome In Pact With BridgeBio’s PellePharm
Shoreline picks up technology platform rights and access from Editas, which recently reduced staff. Hyloris out-licenses commercial rights to Maxigesic in nine EU markets to Salus.
- Medical Devices
- Other Names / Subsidiaries
- Jiangsu T-mab BioPharma Co., Ltd.
- Maiwei (Shanghai) Biotechnology, Mabwell (Shanghai) Bioscience Co. Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.